News

Cancer Research UK Partners with Nxera on Next-Stage Trial for HTL0039732

September 17, 2025

The Phase IIa study will test HTL0039732 in combination with immunotherapy to boost responses in resistant solid tumors and broaden treatment choices.

Sanner Previews CPHI Frankfurt Portfolio of CDMO Services, Packaging Innovations

September 17, 2025

The company has expanded its CDMO offerings in recent years, adding to decades of experiences in solutions such as moisture management.

Lilly, Novo, Hims Get FDA Warnings About Misleading Drug Communications

September 16, 2025

Misleading promotions of GLP-1 and compounded semaglutide products are drawing renewed regulatory scrutiny over risk disclosure and safety messaging.

FDA Approves Cortasis Nasal Spray, Enbumyst, for Edema

September 16, 2025

Corstasis Therapeutics plans to launch the product in the United States in the fourth quarter of 2025.

Competition in MASH Is Heating Up as GLP-1s Gate-Crash the Party

September 15, 2025

Novo Nordisk’s Wegovy will be competing with Madrigal Pharmaceuticals’ Rezdiffra in the metabolic dysfunction-associated steatohepatitis arena.

Op/Ed: Rethinking R&D Tax Relief–Why Smarter Incentives Are Key to Unlocking UK Pharma Innovation

September 15, 2025

UK pharma small- and medium-sized enterprises face funding and R&D barriers. Improved tax relief and targeted incentives are vital to keep UK innovation competitive.

CPHI Frankfurt Expected to Draw More Than 60,000 Attendees in October

September 12, 2025

The 2024 edition of the annual conference, held in Milan, attracted more than 59,000 professionals from across the bio/pharmaceutical landscape.

FDA Abandoning Expert Reviews: Implications for Drug Developers and Quality Professionals

September 12, 2025

This potential shift has profound implications for regulatory strategy, transparency, and internal quality systems, directly impacting the core concerns of industry professionals.

PharmTech Weekly Roundup – Week of September 8, 2025

September 12, 2025

Pharma embraces AI for quality, supply chain, and training; navigates FDA compliance; and develops new treatments like an epinephrine nasal spray.

Medicines Discovery Catapult and Crown Bioscience Create Alliance for Radiopharmaceuticals

September 12, 2025

The two organizations are collaborating on an integrated translational biology platform for the development of radiopharmaceuticals.